Jaume Pons

1.5k total citations
23 papers, 949 citations indexed

About

Jaume Pons is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Jaume Pons has authored 23 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 10 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Oncology. Recurrent topics in Jaume Pons's work include Phagocytosis and Immune Regulation (13 papers), Immunotherapy and Immune Responses (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jaume Pons is often cited by papers focused on Phagocytosis and Immune Regulation (13 papers), Immunotherapy and Immune Responses (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jaume Pons collaborates with scholars based in United States, South Korea and Belgium. Jaume Pons's co-authors include Yasmina Abdiche, Ons Harrabi, Arvind Rajpal, Hong Wan, Sangeetha Bollini, Tracy C. Kuo, Pavel Strop, Kevin C. Lindquist, Amy Chen and Emma Sangalang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jaume Pons

22 papers receiving 921 citations

Peers

Jaume Pons
John Mandeville United States
Jinjung Choi South Korea
Matthew Lovatt Singapore
T L Knisely United States
Vinodh Kakkassery Germany
Daiju Iwata Japan
Zahra Sadrai United States
Mark Tornetta United States
Yaohong Tan United States
Hongkang Xi United States
John Mandeville United States
Jaume Pons
Citations per year, relative to Jaume Pons Jaume Pons (= 1×) peers John Mandeville

Countries citing papers authored by Jaume Pons

Since Specialization
Citations

This map shows the geographic impact of Jaume Pons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Pons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Pons more than expected).

Fields of papers citing papers by Jaume Pons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Pons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Pons. The network helps show where Jaume Pons may publish in the future.

Co-authorship network of co-authors of Jaume Pons

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Pons. A scholar is included among the top collaborators of Jaume Pons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Pons. Jaume Pons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garcia‐Manero, Guillermo, Harry P. Erba, Jessica K. Altman, et al.. (2021). Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02). Blood. 138(Supplement 1). 2601–2601. 11 indexed citations
2.
Kuo, Tracy C., Amy Chen, Ons Harrabi, et al.. (2020). Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology. 13(1). 160–160. 58 indexed citations
3.
Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2020). ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 13–14. 23 indexed citations
4.
Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2020). 615 Targeted immune cell activation by systemic delivery of toll-like receptor 9 agonist antibody conjugates induce potent anti-tumor immunity. SHILAP Revista de lepidopterología. A369.2–A370.
5.
Chow, Laura Q.M., Justin F. Gainor, Nehal J. Lakhani, et al.. (2020). A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. Journal of Clinical Oncology. 38(15_suppl). 3056–3056. 18 indexed citations
6.
Chen, Amy, Ons Harrabi, Abraham Fong, et al.. (2020). ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies. Blood. 136(Supplement 1). 15–16. 3 indexed citations
7.
Sockolosky, Jonathan T., Emma Sangalang, Shelley Izquierdo, et al.. (2019). Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα. mAbs. 11(6). 1036–1052. 39 indexed citations
8.
Chow, Laura Q.M., Justin F. Gainor, Nehal J. Lakhani, et al.. (2019). A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. Journal of Clinical Oncology. 37(15_suppl). 2514–2514. 13 indexed citations
9.
Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2019). A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1953–1953. 19 indexed citations
10.
Kauder, Steven E., Tracy C. Kuo, Ons Harrabi, et al.. (2018). ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE. 13(8). e0201832–e0201832. 121 indexed citations
11.
Blarcom, Thomas Van, Andrea Rossi, Davide Foletti, et al.. (2018). Epitope Mapping Using Yeast Display and Next Generation Sequencing. Methods in molecular biology. 1785. 89–118. 8 indexed citations
12.
Lakhani, Nehal J., Patricia LoRusso, Navid Hafez, et al.. (2018). A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 3068–3068. 14 indexed citations
13.
DeVay, Rachel M., Kathy Delaria, Guoyun Zhu, et al.. (2017). Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. Bioconjugate Chemistry. 28(4). 1102–1114. 42 indexed citations
14.
15.
Yeung, Yik A., Davide Foletti, Xiaodi Deng, et al.. (2016). Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire. Nature Communications. 7(1). 13376–13376. 30 indexed citations
16.
Abdiche, Yasmina, Yik A. Yeung, Javier Chaparro‐Riggers, et al.. (2015). The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs. 7(2). 331–343. 154 indexed citations
17.
Blarcom, Thomas Van, Andrea Rossi, Davide Foletti, et al.. (2014). Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Display and Next-Generation Sequencing. Journal of Molecular Biology. 427(6). 1513–1534. 50 indexed citations
18.
Ding, Jindong, Lincoln V. Johnson, Rolf Herrmann, et al.. (2011). Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proceedings of the National Academy of Sciences. 108(28). E279–87. 175 indexed citations
19.
Abdiche, Yasmina, et al.. (2010). Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis. Analytical Biochemistry. 411(1). 139–151. 27 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Mandeville Breakdown of academic impact, for papers by Jinjung Choi Breakdown of academic impact, for papers by Matthew Lovatt Breakdown of academic impact, for papers by T L Knisely Breakdown of academic impact, for papers by Vinodh Kakkassery Breakdown of academic impact, for papers by Daiju Iwata Breakdown of academic impact, for papers by Zahra Sadrai Breakdown of academic impact, for papers by Mark Tornetta Breakdown of academic impact, for papers by Yaohong Tan Breakdown of academic impact, for papers by Hongkang Xi
Rankless by CCL
2026